+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Somatostatin Analogues Market by Product Type (Lanreotide Autogel, Octreotide LAR, Pasireotide LAR), Indication (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Long-acting Somatostatin Analogues Market by Product Type (Lanreotide Autogel, Octreotide LAR, Pasireotide LAR), Indication (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
New

Long-acting Somatostatin Analogues Market by Product Type (Lanreotide Autogel, Octreotide LAR, Pasireotide LAR), Indication (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6117597
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Long-acting somatostatin analogues have emerged as transformative agents in the management of complex endocrine disorders, offering sustained hormone suppression and improved patient adherence. These formulations, engineered to release active compounds over extended periods, address the limitations of short-acting injections and frequent dosing schedules, thereby enhancing quality of life for individuals battling conditions such as acromegaly, Cushing’s disease, and neuroendocrine tumors.

The introduction of lanreotide autogel, octreotide LAR, and pasireotide LAR has shifted therapeutic paradigms, enabling clinicians to tailor treatment regimens based on pharmacokinetic profiles, receptor binding affinities, and patient-specific factors. As healthcare systems emphasize value-based care, these analogues have gained traction through demonstrated reductions in hormone hypersecretion, tumor proliferation, and associated comorbidities. Looking ahead, pipeline innovations and formulation enhancements are poised to further refine safety, efficacy, and delivery mechanisms, underscoring the vital role of these agents in evolving endocrine treatment algorithms.

Against this backdrop, stakeholders must remain attuned to regulatory developments, competitive dynamics, and patient-centric considerations that will shape adoption rates and clinical outcomes. This introduction establishes a foundation for exploring the strategic landscape, emerging shifts, and actionable insights that can optimize market positioning and unlock new growth opportunities within this specialized therapeutic sector.

Unveiling the Transformative Shifts Redefining Therapeutic Paradigms for Long-acting Somatostatin Analogues Innovative Development, Seamless Clinical Integration

The landscape of long-acting somatostatin analogues has undergone a series of transformative shifts driven by advances in molecular engineering, patient-centered delivery, and integrated digital health solutions. Innovations in release technologies now enable precise modulation of dosage windows, reducing peak-trough fluctuations and enhancing tolerability. Concurrently, biomarker-guided dosing strategies have begun to personalize treatment intensity and duration, marking a shift toward precision endocrinology.

Clinical practice has also embraced novel administration approaches, integrating patient support programs that leverage remote monitoring and adherence analytics. As real-world evidence accumulates, payers and clinicians are aligning on value-based contracts that incentivize positive outcomes rather than volume. This paradigm shift underscores a movement away from one-size-fits-all protocols toward customized therapeutic journeys that optimize both clinical efficacy and economic sustainability.

Moreover, heightened emphasis on competitive biosimilar entrants and next-generation analogues is fostering a dynamic environment where collaboration and strategic licensing define market leadership. As stakeholders navigate these changes, a keen understanding of development pipelines, regulatory pathways, and digital enablers will be essential for maintaining a competitive edge in an increasingly sophisticated treatment ecosystem.

Assessing the Far-reaching Consequences of 2025 US Tariff Reforms on Supply Chain Resilience and Cost Structures in Somatostatin Analogue Manufacturing

The introduction of new tariff structures in 2025 has imposed significant operational and financial pressures on the supply chain for somatostatin analogues, particularly those reliant on imported active pharmaceutical ingredients. Manufacturing facilities are evaluating alternative sourcing strategies to mitigate cost inflation, which has prompted a reassessment of supplier portfolios and increased interest in onshore production capabilities.

Procurement teams are now negotiating long-term agreements with key raw material providers and exploring partnerships that secure preferential pricing and volume discounts. These supply chain adaptations not only aim to stabilize margins but also to ensure uninterrupted availability of critical therapies. As cost structures evolve, contract models with healthcare payers are being revisited to reflect new realities, reinforcing the importance of transparent cost analyses and stakeholder collaboration.

In parallel, research and development investment decisions are increasingly influenced by tariff-related risk assessments, with some companies accelerating local capabilities and others consolidating manufacturing footprints to achieve economies of scale. Ultimately, these cumulative impacts underscore the necessity of agile strategies that align production flexibility with sustainable cost management in the face of shifting trade policies.

Deciphering Critical Patient and Product Segmentation Dimensions Driving Differential Utilization Patterns in Somatostatin Analogue Treatment Pathways

An in-depth examination of product type dimensions reveals that lanreotide autogel, octreotide LAR, and pasireotide LAR each command distinct clinical and commercial profiles, informed by half-life variances, receptor selectivity, and patient tolerance. Treatment patterns vary accordingly, with certain patient cohorts demonstrating a preference for autogel formulations that facilitate self-administration, while others remain aligned with intramuscular injection regimens under supervised care.

Within clinical indications, acromegaly and Cushing’s disease continue to drive foundational demand, whereas the segment encompassing neuroendocrine tumors-including gastroenteropancreatic and pulmonary subtypes-has exhibited heightened complexity due to differing tumor biology and staging requirements. Tailoring therapy to these divergent subpopulations necessitates nuanced dosing algorithms and monitoring protocols, reflecting the heterogeneity inherent in neuroendocrine pathology.

Patient administration routes further stratify the market, with deep subcutaneous injections gaining traction for their convenience and reduced injection-site complications compared to intramuscular techniques. Distribution channels extend across hospital pharmacies, mail order services, and retail outlets, each balancing factors such as inventory management, patient access, and reimbursement mechanisms. Finally, adult and pediatric age groups present unique considerations in dosing frequency and support needs, underscoring the importance of segmented strategies that address both efficacy outcomes and quality-of-life imperatives.

Uncovering Region-specific Growth Drivers, Access Dynamics, and Reimbursement Landscapes Shaping the Adoption of Long-acting Somatostatin Analogues Globally

Regional dynamics in the somatostatin analogue market are shaped by varying healthcare infrastructures, reimbursement environments, and disease prevalence. In the Americas, established specialty centers drive robust adoption, supported by comprehensive insurance frameworks and well-defined clinical guidelines that facilitate rapid uptake of extended-release formulations.

Across Europe, the Middle East, and Africa, country-level variations in regulatory approval timelines and budgetary constraints influence market penetration, with innovative cost-containment programs emerging to balance patient access against national healthcare expenditures. Strategic collaborations with regional distributors and patient support initiatives prove essential to overcoming logistical complexities and diverse reimbursement policies.

Asia-Pacific presents a tapestry of opportunities, where rising awareness of neuroendocrine disorders and expanding hospital networks catalyze demand for advanced therapies. Local manufacturing partnerships and government-backed healthcare reforms have further accelerated market entry for long-acting analogues, offering a compelling growth trajectory driven by increasing public and private sector investment in chronic disease management.

Analyzing Strategic Competitive Positions, Innovative Portfolios, and Collaborative Ventures Among Leading Somatostatin Analogue Developers and Market Entrants

Leading pharmaceutical developers and emerging biotechs are vying for strategic advantage through differentiated portfolios, strategic alliances, and pipeline diversification. Established players leverage legacy formulations while investing in reformulations that extend release profiles and enhance patient convenience, aiming to solidify market share amid biosimilar competition.

Several companies have forged co-development agreements to expand global reach, tapping into regional R&D centers and regulatory expertise to expedite approvals. Others are building patient engagement platforms that integrate digital adherence tools, real-time monitoring, and telemedicine support, thereby reinforcing brand loyalty and gathering valuable real-world data.

Meanwhile, a cohort of specialized firms is advancing next-generation somatostatin analogues with novel receptor affinities and combination therapy potential, positioning themselves as innovators in unmet endocrine and oncology segments. These competitive moves reflect a broader industry trend toward collaborative ecosystems, where shared risk and resource optimization are driving accelerated progress from molecule discovery to market launch.

Implementing Targeted Strategies to Enhance Market Access, Elevate Clinical Value, and Address Regulatory and Tariff Challenges for Sustained Commercial Growth

Industry leaders should prioritize the establishment of integrated market access frameworks that align with evolving payer models, emphasizing outcome-based agreements and data-driven value propositions. Investing in real-world evidence generation will substantiate therapeutic benefits and support pricing negotiations, while proactive engagement with health technology assessment bodies can streamline reimbursement pathways.

Supply chain resilience can be bolstered by diversifying raw material sources and adopting dual-site manufacturing to mitigate geo-political risks. Enhanced patient support services, incorporating digital tools for adherence tracking and virtual consultations, will foster sustained engagement and improved clinical endpoints. Additionally, forging alliances with contract research organizations and local manufacturing partners can accelerate product launches across emerging markets.

Finally, multi-stakeholder collaborations that integrate academic research, clinical advocacy groups, and regulatory agencies will facilitate the co-development of novel analogues and combination regimens, positioning companies to address unmet needs and differentiate offerings in a competitive landscape.

Outlining the Multi-stage Research Methodology Employed to Deliver Rigorous Evidence and Unbiased Insights on Somatostatin Analogues

The research methodology underpinning this analysis combined comprehensive secondary research with rigorous primary interviews conducted among key opinion leaders, healthcare payers, and industry executives. Secondary sources included peer-reviewed publications, regulatory filings, clinical trial registries, and pharmacovigilance databases, ensuring a robust foundation of scientific and market intelligence.

Primary engagement involved structured interviews and roundtables with endocrinologists, hospital pharmacists, and portfolio managers, yielding qualitative insights into prescribing behaviors, supply chain bottlenecks, and reimbursement drivers. Quantitative data were validated through cross-referencing with public financial disclosures and sales reports, followed by triangulation to confirm consistency across multiple sources.

This multi-stage approach was augmented by regional validation workshops to capture nuances in healthcare delivery, distribution models, and patient demographics. Rigorous data cleansing and analyst peer reviews were conducted at each phase to uphold data integrity and analytical accuracy, resulting in a comprehensive, evidence-based assessment of the long-acting somatostatin analogue landscape.

Synthesizing the Complex Interplay of Innovation, Market Dynamics, and Strategic Imperatives in the Somatostatin Analogue Ecosystem

The evolution of long-acting somatostatin analogues reflects a confluence of scientific innovation, patient-centric delivery models, and dynamic market forces. Advances in formulation science, coupled with precision dosing strategies and supportive digital platforms, are redefining treatment standards for acromegaly, Cushing’s disease, and neuroendocrine tumors.

Tariff reforms have underscored the importance of diversification and agile operations, prompting stakeholders to reexamine supply chain architectures and cost management approaches. Segmentation analysis has highlighted critical variations across product types, clinical indications, administration routes, distribution channels, and patient age groups, guiding tailored strategies to maximize therapeutic impact.

Regional insights reveal distinct adoption patterns influenced by regulatory frameworks, reimbursement policies, and infrastructure maturity. Competitive dynamics are characterized by strategic partnerships, portfolio optimization, and emerging biosimilar and next-generation entrants. Collectively, these factors underscore a complex, opportunity-rich environment that rewards evidence-based decision-making and collaborative innovation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Product Type
    • Lanreotide Autogel
    • Octreotide LAR
    • Pasireotide LAR
  • Indication
    • Acromegaly
    • Cushing's Disease
    • Neuroendocrine Tumors
      • Gastroenteropancreatic NETs
      • Pulmonary NETs
  • Route Of Administration
    • Deep Subcutaneous Injection
    • Intramuscular Injection
  • Distribution Channel
    • Hospital Pharmacies
    • Mail Order Pharmacies
    • Retail Pharmacies
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Novartis AG
  • Ipsen S.A.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of long-acting somatostatin analogues in pediatric neuroendocrine tumor management
5.2. Development of novel oral octreotide formulations to improve patient adherence and outcomes
5.3. Advancements in sustained-release delivery systems for pasireotide in acromegaly treatment
5.4. Emerging biosimilar approvals disrupting the long-acting somatostatin analogue pricing landscape
5.5. Integration of real-world evidence to tailor long-acting somatostatin analogue dosing strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting Somatostatin Analogues Market, by Product Type
8.1. Introduction
8.2. Lanreotide Autogel
8.3. Octreotide LAR
8.4. Pasireotide LAR
9. Long-acting Somatostatin Analogues Market, by Indication
9.1. Introduction
9.2. Acromegaly
9.3. Cushing's Disease
9.4. Neuroendocrine Tumors
9.4.1. Gastroenteropancreatic NETs
9.4.2. Pulmonary NETs
10. Long-acting Somatostatin Analogues Market, by Route Of Administration
10.1. Introduction
10.2. Deep Subcutaneous Injection
10.3. Intramuscular Injection
11. Long-acting Somatostatin Analogues Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Mail Order Pharmacies
11.4. Retail Pharmacies
12. Long-acting Somatostatin Analogues Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Long-acting Somatostatin Analogues Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Long-acting Somatostatin Analogues Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Long-acting Somatostatin Analogues Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Ipsen S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHAI
FIGURE 26. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHSTATISTICS
FIGURE 27. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHCONTACTS
FIGURE 28. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 79. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 84. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 85. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 90. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 91. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 158. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 159. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 170. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 171. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 189. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 194. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 195. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 206. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 207. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 254. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 255. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 278. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 279. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 284. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Long-acting Somatostatin Analogues market report include:
  • Novartis AG
  • Ipsen S.A.

Related Topics

Related Reports

Acromegaly Treatment Market by Treatment Type (Combination Therapies, Dopamine Agonists, Growth Hormone Receptor Antagonists), Route Of Administration (Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Acromegaly Treatment Market by Treatment Type (Combination Therapies, Dopamine Agonists, Growth Hormone Receptor Antagonists), Route Of Administration (Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Neuroendocrine Tumor Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Neuroendocrine Tumor Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Gastroenteropancreatic Neuroendocrine Tumors Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035 - Product Image

Gastroenteropancreatic Neuroendocrine Tumors Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Somatostatin Analogs Market by Molecule Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast 2025-2030 - Product Image

Somatostatin Analogs Market by Molecule Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.